Ozempic Cost in New York (2026): Pricing, Insurance, and Savings Options

What Ozempic Actually Costs at a New York Pharmacy

The Novo Nordisk wholesale acquisition cost for Ozempic is $998 per month, regardless of dose. New York retail pharmacies, from chain locations in Manhattan to independent shops on Long Island, price cash-pay fills at that same $998 figure. This price applies equally to the 0.25 mg initiation pen and the 2 mg maintenance pen.

That sticker price has stayed flat since late 2024, when Novo Nordisk committed to a temporary price freeze across its GLP-1 portfolio amid congressional scrutiny. A December 2023 analysis published in Annals of Internal Medicine estimated the cost of manufacturing a month's supply of semaglutide at $0.89 to $4.73, underscoring the gap between production cost and retail pricing [1]. New York's Attorney General office opened a pricing transparency inquiry in 2025 targeting GLP-1 manufacturers, though no enforcement action has followed.

Pharmacy-level pricing in New York does not vary much. GoodRx and similar aggregators show a $920 to $1,010 range at most New York zip codes, with the low end typically found at Costco Pharmacy locations (no membership required for pharmacy services in New York). Mark Cuban's Cost Plus Drugs does not currently stock branded Ozempic.

For patients paying full retail, $998 per month translates to $11,976 per year. That figure makes the insurance and discount strategies covered below a financial necessity for most patients.

New York Insurance Coverage for Ozempic

The majority of commercial health plans sold in New York cover Ozempic for type 2 diabetes, though nearly all require prior authorization. Coverage for off-label weight management is less consistent and often denied without a concurrent diabetes diagnosis.

Empire BlueCross BlueShield, the state's largest commercial carrier, lists Ozempic on its preferred specialty tier with a PA requirement. The PA criteria typically include a documented A1C of 7% or higher, trial of metformin (or documented intolerance), and prescriber attestation that the patient has type 2 diabetes. Approval usually comes within 48 hours for electronic submissions.

UnitedHealthcare and Aetna plans sold through the New York State of Health marketplace follow similar PA pathways. UnitedHealthcare moved Ozempic to a non-preferred tier on several 2026 formularies, which raises copays but does not eliminate coverage.

Oscar Health, a New York-founded insurer with significant metro-area enrollment, covers Ozempic on its specialty tier but requires step therapy through metformin and a sulfonylurea or SGLT2 inhibitor before approval.

Copays after approval range from $25 to $150 per month on most commercial plans, depending on tier placement and plan design. High-deductible health plans may require patients to pay the full negotiated rate (often $700 to $900) until meeting their deductible.

The SUSTAIN clinical trial program demonstrated the efficacy that underpins these coverage decisions. SUSTAIN-7 (N=1,201) showed semaglutide 0.5 mg reduced A1C by 1.5% and semaglutide 1.0 mg reduced A1C by 1.8% versus dulaglutide over 40 weeks [2]. These results, along with demonstrated cardiovascular benefit in the SELECT trial (N=17,604), give insurers the clinical evidence base to justify formulary inclusion [3].

New York Medicaid and Ozempic

New York Medicaid covers Ozempic with prior authorization for members with a type 2 diabetes diagnosis. The coverage extends across both fee-for-service Medicaid and the state's managed care plans, including Healthfirst, Fidelis Care, and MetroPlus.

PA criteria under New York Medicaid align closely with the FDA-approved labeling. The prescriber must document type 2 diabetes (ICD-10 E11.x), current A1C level, and prior or concurrent use of metformin unless contraindicated. Weight management alone does not satisfy the PA criteria under current Medicaid policy.

"New York's Medicaid Drug Utilization Review Board evaluates GLP-1 receptor agonist coverage annually, and the 2026 preferred drug list retains semaglutide with quantity limits aligned to FDA-approved dosing," according to the New York State Department of Health Medicaid pharmacy benefit update published in January 2026 [4].

For the approximately 7.7 million New Yorkers enrolled in Medicaid or the Essential Plan, this coverage eliminates out-of-pocket cost entirely or reduces it to a nominal $1 to $3 copay. The catch is processing time. Medicaid PAs in New York average 3 to 5 business days, longer than most commercial plans. Providers can request expedited review (24-hour turnaround) if clinical urgency is documented.

Patients denied under Medicaid have the right to a fair hearing through the New York Office of Temporary and Disability Assistance. Denial overturn rates for GLP-1 receptor agonists in New York have not been publicly reported, but national data suggests approximately 40 to 60% of GLP-1 PA denials are reversed on appeal when supporting documentation is resubmitted [5].

Compounded Semaglutide in New York: Legal Status and Cost

Compounded semaglutide is available through 503A pharmacies in New York. These pharmacies operate under state board oversight and compound patient-specific prescriptions based on a valid prescriber order.

The price difference is substantial. Compounded semaglutide from a licensed New York 503A pharmacy runs approximately $199 per month, roughly 80% less than branded Ozempic. The compounded product is a subcutaneous injection mixed to the prescribed concentration at the pharmacy.

New York's regulatory framework for compounding is stricter than many states. The New York State Board of Pharmacy requires 503A pharmacies to maintain a bona fide prescriber-patient relationship for each compounded prescription, prohibits bulk compounding without individual patient orders (that function belongs to 503B outsourcing facilities under FDA jurisdiction), and conducts routine inspections. The Board issued guidance in 2025 reaffirming that semaglutide compounding is permitted when a legitimate shortage exists or when a patient has a documented medical need for a formulation not commercially available [6].

The FDA's position on compounded semaglutide has shifted. In October 2024, the FDA removed semaglutide from its drug shortage list, which technically limits the legal basis for 503A compounding under the Federal Food, Drug, and Cosmetic Act. Compounding pharmacies and their trade groups have challenged this determination in court, and as of May 2026, litigation is ongoing. New York pharmacies that continue compounding semaglutide generally rely on the patient-specific exception or the state's independent authority to regulate pharmacy practice.

Patients considering compounded semaglutide should confirm three things: the pharmacy holds a current New York State license, the pharmacy is registered as a 503A facility, and the prescribing provider has evaluated the patient directly (telemedicine visits satisfy this requirement in New York). The Endocrine Society has stated that patients using compounded peptides should be monitored with the same clinical rigor as those on branded products [7].

The Novo Nordisk Savings Card and Other Discount Programs

The Novo Nordisk savings card remains the single most impactful cost-reduction tool for commercially insured New York patients. Eligible patients pay as little as $25 for a 1-month or 3-month supply. The card covers up to $150 per month in out-of-pocket cost after insurance.

Eligibility criteria: the patient must have commercial insurance that covers Ozempic, cannot be enrolled in any federal or state government insurance program (Medicare, Medicaid, Tricare, VA), and must have a valid prescription. The card is available at novomedlink.com and activates at the pharmacy counter.

"For patients with commercial coverage and a copay between $25 and $175 per month, the savings card effectively reduces their cost to $25. This is the first option I discuss with every newly prescribed patient," said Dr. Caroline Apovian, co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, in a 2024 interview with Endocrine Today.

Additional discount pathways for New York residents:

NovoCare Patient Assistance Program (PAP). Uninsured patients with household income at or below 400% of the federal poverty level ($62,400 for an individual in 2026) may qualify for free Ozempic. The application requires income verification and a prescriber signature. Processing takes 2 to 4 weeks.

New York State Pharmaceutical Assistance Programs. The Elderly Pharmaceutical Insurance Coverage (EPIC) program provides supplemental coverage for Medicare-enrolled New Yorkers aged 65 and older. EPIC can reduce Medicare Part D copays for Ozempic, though the drug must be on the member's Part D formulary.

340B Pricing. Patients who receive care at 340B-eligible facilities (federally qualified health centers, certain hospital outpatient departments) may access Ozempic at significantly reduced cost. New York City alone has over 70 FQHC sites participating in the 340B program.

Ozempic via Telehealth in New York

New York permits telehealth prescribing of Ozempic. The state's telehealth parity law, updated in 2023, requires insurers to cover telehealth-delivered services at the same rate as in-person visits. This means a telehealth consultation that results in an Ozempic prescription is covered the same way an office visit would be.

Several telehealth platforms serve New York patients seeking GLP-1 prescriptions. HealthRX provides physician-supervised evaluations for semaglutide therapy, including lab review and ongoing monitoring, with prescriptions sent to the patient's preferred New York pharmacy. The initial consultation typically includes A1C and metabolic panel review, BMI documentation, and medical history assessment.

New York does not require an initial in-person visit before a telehealth prescriber can write a controlled or non-controlled prescription. Since Ozempic is not a scheduled substance, a video or audio-only visit is sufficient under New York Education Law §6801 and the state's telehealth practice guidelines.

One practical consideration: if the telehealth provider prescribes branded Ozempic, the patient can fill at any New York retail pharmacy. If the provider writes for compounded semaglutide, the patient must use a 503A pharmacy licensed in New York or a 503B outsourcing facility registered with the FDA.

How New York Pricing Compares to National Averages

New York's Ozempic pricing tracks closely with the national average. The $998 list price is uniform across all 50 states. Where New York diverges is in the cost of living adjustments that affect adjacent expenses, specifically, the cost of the prescriber visit and any required lab work.

A new-patient endocrinology visit in Manhattan averages $350 to $500 without insurance, compared to a national average of $250 to $350 [8]. Telehealth visits reduce this gap significantly, with most platforms charging $99 to $199 for an initial GLP-1 evaluation.

On the compounded semaglutide side, New York's 503A pharmacy pricing ($199 per month) is comparable to the $150 to $250 national range. Texas and Florida, which have larger compounding pharmacy markets, trend toward the lower end. New York's stricter oversight may contribute to slightly higher compounding costs, but also provides an additional layer of quality assurance.

New York patients have one structural advantage: the state's insurance market is heavily regulated under community rating laws, meaning insurers cannot charge higher premiums based on health status. This makes it easier for patients with type 2 diabetes to obtain comprehensive coverage that includes GLP-1 receptor agonists without prohibitive premium surcharges.

Step-by-Step: Reducing Your Ozempic Cost in New York

A practical decision tree for New York patients:

Step 1: Check your formulary. Call the number on the back of your insurance card and ask whether Ozempic (semaglutide) is on your plan's formulary and what tier it occupies. Ask specifically about PA requirements.

Step 2: Request prior authorization. Your prescriber submits the PA. Provide your most recent A1C result, a list of current diabetes medications, and any documented metformin intolerance. Expect a 2 to 5 day turnaround.

Step 3: Apply the savings card. If commercially insured and approved, register at novomedlink.com and present the card at your pharmacy. Confirm the copay drops to $25.

Step 4: Appeal if denied. If PA is denied, request the specific denial reason in writing. Your prescriber can submit a peer-to-peer review or formal appeal with supporting clinical notes. Reference the ADA Standards of Care, which recommend GLP-1 receptor agonists as second-line therapy for type 2 diabetes after metformin [9].

Step 5: Explore compounded semaglutide. If uninsured or facing high out-of-pocket costs after insurance, discuss compounded semaglutide with your provider. Confirm the pharmacy is a licensed New York 503A facility.

Step 6: Apply for patient assistance. If uninsured and income-eligible, submit a NovoCare PAP application for potential free branded Ozempic.

The A1C reduction benefit of semaglutide is dose-dependent. SUSTAIN-7 demonstrated that the 1.0 mg dose produced a 1.8% A1C reduction versus a 1.4% reduction with dulaglutide 1.5 mg [2]. For patients with a starting A1C above 8%, this difference can mean reaching the ADA target of <7% on semaglutide alone versus requiring additional agents on alternatives. Cost decisions should account for this efficacy differential.